Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuraxis (NRXS) EBITDA (2022 - 2025)

Historic EBITDA for Neuraxis (NRXS) over the last 4 years, with Q3 2025 value amounting to -$2.1 million.

  • Neuraxis' EBITDA fell 2717.98% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.6 million, marking a year-over-year decrease of 363.99%. This contributed to the annual value of -$7.2 million for FY2024, which is 738.72% down from last year.
  • Per Neuraxis' latest filing, its EBITDA stood at -$2.1 million for Q3 2025, which was down 2717.98% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, Neuraxis' EBITDA ranged from a high of -$669582.0 in Q2 2022 and a low of -$3.0 million during Q3 2023
  • Moreover, its 4-year median value for EBITDA was -$1.6 million (2023), whereas its average is -$1.6 million.
  • In the last 5 years, Neuraxis' EBITDA tumbled by 15120.76% in 2023 and then soared by 4536.44% in 2024.
  • Neuraxis' EBITDA (Quarter) stood at -$986226.0 in 2022, then crashed by 64.59% to -$1.6 million in 2023, then rose by 9.65% to -$1.5 million in 2024, then crashed by 43.19% to -$2.1 million in 2025.
  • Its EBITDA was -$2.1 million in Q3 2025, compared to -$1.7 million in Q2 2025 and -$2.3 million in Q1 2025.